Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as [14C]-MRM-3379, Low dose of MRM-3379
MRM-3379 · 1 trial · 1 indication
Evaluate the cumulative and total radioactivity in urine and feces following administration of a single oral dose of radiolabeled MRM-3379.
| Arm | Type | Description |
|---|---|---|
| Healthy Male Volunteers | EXPERIMENTAL | Participants in this arm will receive a single dose of 5 mg \[14C\]-MRM-3379. |
| Name | Type | Description |
|---|---|---|
| [14C]-MRM-3379 | DRUG | Oral capsule administered on Day 1 only. |
Inclusion Criteria: 1. Male of any race, between 18 and 55 years of age, inclusive. 2. Body mass index between 18.0 and 32.0 kg/m2, inclusive, and a body weight between 50 and 110 kg, inclusive. 3. In good health, as determined by medical history, and as assessed by the investigator (or designee). ...
MRM-3379 is an investigational small molecule being studied for Fragile X Syndrome, a rare genetic condition. It is currently in Phase 2 clinical development, with an active trial evaluating its effects in male participants aged 13 years and older with Fragile X Syndrome.
MRM-3379 targets PDE4D, an enzyme involved in cellular signaling pathways. By inhibiting PDE4D, the drug aims to modulate these pathways, which may be relevant to the treatment of Fragile X Syndrome.
MRM-3379 is being developed by Mirum Pharmaceuticals, Inc., a biopharmaceutical company traded on the NASDAQ under the ticker symbol MIRM. The company is conducting clinical trials to evaluate the drug's safety and efficacy.
MRM-3379 is in Phase 2 clinical development for Fragile X Syndrome. It is also being studied in a Phase 1 trial in healthy volunteers to evaluate its absorption, distribution, metabolism, and excretion. The drug is investigational and not yet approved.
MRM-3379 is being studied in two clinical trials. NCT07209462 is a Phase 2 study in male participants with Fragile X Syndrome, and NCT07712718 is a Phase 1 study of [14C]-MRM-3379 in healthy male volunteers to assess its pharmacokinetics.
MRM-3379 and [14C]-MRM-3379 are related forms of the same drug. [14C]-MRM-3379 is a radiolabeled version used in a Phase 1 study to track the drug's absorption, distribution, metabolism, and excretion in healthy volunteers.